Jazz Pharmaceuticals PLC
JAZZ
View Detailed Chart
185.010USD
+2.690+1.48%
Close 03/24, 16:00（ET）Quotes delayed by 15 min
10.50BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.48%
5 Days
+2.01%
1 Month
+6.43%
6 Months
+42.77%
Year to Date
+8.83%
1 Year
+30.27%
View Detailed Chart
TradingKey Stock Score of Jazz Pharmaceuticals PLC
Currency: USD Updated: 2026-03-24Key Insights
Jazz Pharmaceuticals PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 3 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 223.65.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Jazz Pharmaceuticals PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Jazz Pharmaceuticals PLC Highlights
StrengthsRisks
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -31.68, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 62.79M shares, decreasing 12.60% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 11.73K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.17.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
223.653
Target Price
+23.82%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Jazz Pharmaceuticals PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Jazz Pharmaceuticals PLC Info
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Ticker SymbolJAZZ
CompanyJazz Pharmaceuticals PLC
CEOGala (Renee D)
Websitehttps://www.jazzpharma.com/
Related Instruments
-0.83%
+0.56%
-0.06%
+0.93%
+0.60%
+0.13%
+0.35%
-0.38%
+0.56%
+0.71%
+0.19%
+0.83%
+1.85%
+0.68%
-0.58%
0.00%
+0.40%
+0.70%
+0.61%
+1.01%Popular Symbols
251.640
+0.150 (+0.06%)
175.200
-0.440 (-0.25%)
71169.040
+1105.850 (+1.58%)
301.050
+6.260 (+2.12%)
2168.410
+22.430 (+1.04%)
383.030
+2.180 (+0.57%)
4551.160
+80.660 (+1.80%)
88.799
+0.696 (+0.79%)
1.159
-0.001 (-0.12%)
159.007
+0.312 (+0.20%)
